BSAC Welcomes G20 Leaders’ Declaration on Combating AMR
The British Society for Antimicrobial Chemotherapy (BSAC) has welcomed the publication of the G20 Leaders’ Declaration, which followed high-level meetings in Hamburg on July 7 to 8, 2017. BSAC stands ready to support, wherever it can, the renewed focus on National Action Plans, public awareness, and the call for a global research and development hub.
Here is the section on Combating Antimicrobial Resistance (AMR) in full:
“AMR represents a growing threat to public health and economic growth. To tackle the spread of AMR in humans, animals and the environment, we aim to have implementation of our National Action Plans, based on a One-Health approach, well under way by the end of 2018. We will promote the prudent use of antibiotics in all sectors and strive to restrict their use in veterinary medicine to therapeutic uses alone. Responsible and prudent use of antibiotics in food producing animals does not include the use for growth promotion in the absence of risk analysis. We underline that treatments should be available through prescription or the veterinary equivalent only. We will strengthen public awareness, infection prevention and control and improve the understanding of the issue of antimicrobials in the environment. We will promote access to affordable and quality antimicrobials, vaccines and diagnostics, including through efforts to preserve existing therapeutic options. We highlight the importance of fostering R&D, in particular for priority pathogens as identified by the WHO and tuberculosis. We call for a new international R&D Collaboration Hub to maximise the impact of existing and new antimicrobial basic and clinical research initiatives as well as product development. We invite all interested countries and partners to join this new initiative. Concurrently, in collaboration with relevant experts including from the OECD and the WHO, we will further examine practical market incentive options.”